Evaluation of method of measuring serum insulin glargine concentration after subcutaneous administration of insulin glargine in healthy male subjects.

Not Applicable

• Conditions: Diabetes Mellitus

• Registration Number: JPRN-UMIN000009540
• Lead Sponsor: Medical Co. LTA, Clinical Pharmacology Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-12-15
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: Male
• Target Recruitment: 6

Inclusion Criteria

Not provided

Exclusion Criteria

1, Subjects with present illness which requires treatment. 2, Subjects with past medical history which was considered not adequate for this study. 3, Subjects with past history of drug allergy. 4, Subjects who took prescribed medicine and/or OTC drug 1 week prior to admission to the clinic. 5. Subjects who donated and/or withdrawn whole blood more than 400mL within 12 weeks, 200mL within 4 weeks, and/or blood component within 2 weeks prior to admission. 6, Subjects who were participated in a clinical trial and administered new compound study drug within 4 weeks, or any kind of study drug within 3 weeks prior to admission. 7, Subjects with history of alcohol and/or drug abuse. 8, Subjects who was judged not appropriate for this study by study physician.

Study & Design

• Study Type: Interventional
• Study Design: Not specified